MedTrace Logo

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

NCT00799682 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2011-07-21

No results posted yet for this study

Summary

The purpose of this study is to determine if there is a difference in the ocular signs and symptoms of subjects' eyes using Xalatan® 0.005% versus Travatan Z® 0.004% based on the outcome of subject assessment and clinical assessment in patients with Ocular Hypertension or Glaucoma with mild to moderate dry eye at baseline in accordance with the Oxford Grading Scale.

Conditions

Interventions

DRUG

Xalatan

0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.

DRUG

Travatan Z

0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ophthalmic Consultants of Long Island

    lead OTHER

Principal Investigators

  • Marguerite McDonald, M.D. · Ophthalmic Consultants of Long Island

  • Barbara Burger, R.N. · Ophthalmic Consultans of Long Island

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-01-31
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799682 on ClinicalTrials.gov